Graftys news

GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, announces today the opening of its new preparation and logistic site in Liège (Belgium). Continuously strengthening its manufacturing capability and reinforcing its logistic services to improve the quality of its products and the performance of the deliveries, the Graftys Liège site will start kit preparation and logistic activities, in parallel with the French facilities in Aix-en-Provence, from the

GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is proud to announce that as a fruitful result of 10 years’ partnership with its distributor - LAS Brasil, the milestone of 10,000 units of GRAFTYS® HBS sold in Brazil has been crossed during the third quarter of 2020. GRAFTYS® HBS is a calcium phosphate bone graft substitute, which offers very low viscosity to facilitate remote injections into closed bone cavities. GRAFTYS® HBS is a macroporous

GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is pleased to announce the CE recertification in Europe and the certification of its Quality Management System in conformity with the Medical Device Single Audit Program (MDSAP) in Australia, Brazil, Canada and the United States of America for the Design, Manufacture and Distribution of its Sterile Calcium Phosphate Resorbable Bone Void Fillers and related Delivery Systems.

GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, today announces a new distribution agreement for its bestselling product Graftys® QuickSet in the US territory. Responding to a medical need and to a direct request from orthopedic surgeons, Graftys® QuickSet, a new generation macroporous calcium phosphate cement which will be distributed in the USA under the tradename QuickPack™ by OrthoPediatrics Corp. (“OrthoPediatrics”), displays an o

Graftys, a French Société Anonyme specialized in the development, manufacturing and commercialization of synthetic orthopedic biomaterials, announced today the appointment of its Chairman of the Board, Gilles Alberici, as Chief Executive Officer, effective January 20, 2016. Aurélien Valet has been appointed deputy CEO. 

Aix-en-Provence, November 16th, 2015 – GRAFTYS SA, a company which develops and commercializes biomaterials used in orthopedic surgery, announces that it has recently established an ambitious Post Marketing Surveillance program, in the form of an internationally based registry of patients who have received implants of GRAFTYS® HBS and GRAFTYS® QuickSet. Both of these advanced phosphocalcic cements are highly injectable and resorbable. This registry will put into practice «

Aix-en-Provence, September 14th, 2015 – GRAFTYS SA, a company focused on development and commercialization of orthopedic biomaterials, is pleased to announce that it has obtained authorization from its notified body, NSAI (National Standards Authority of Ireland) for European commercialization for two of its cements (GRAFTYS® HBS and GRAFTYS® Quickset) for treatment of bone marrow lesions caused by traumatic injury. GRAFTYS® HBS and GRAFTYS® Quickset are highly injectabl